DR30206 is designed as a tri-specific antibody of anti-PDL1/VEGF /TGF-β based on MultipleBody® platform. it can simultaneously antagonize three targets: PDL1, VEGF and TGF-β, has dual effects of inhibiting neovascularization and relieving immunosuppression. It is intended to be used in the treatment of diverse solid tumors.DR30206 clinical trial in China was approved by the NMPA in June 2023 and is underway in Phase I clinical studies in China.
Claudin 18.2 (CLDN18.2) is specifically expressed in highly differentiated normal gastric mucosa, but also in gastric and pancreatic cancer. Due to the tight adhesion between cells, it is very difficult for antibody drugs to bind to normal tissues. However, the loose structure of the interstitial space of cancer cells makes CLDN18.2 possible to be exposed to macromolecular protein drugs, so CLDN18.2 is an ideal target for a new generation of anti-tumor therapy. DR30303 is a fusion protein composed of single domain antibody and human Fc and specifically recognizes the of CLDN18.2. It has a killing effect on CLDN18.2 positive tumor cells through ADCC and CDC. At the same time, due to the characteristics of the target, it also reduces the toxicity to normal CLDN18.2 positive tissues. It is intended to be used in the treatment of gastric cancer and other solid tumors with abnormal expression of CLDN18.2.
DR30303 clinical trial in China was approved by the NMPA in January 2022 and is underway in Phase I clinical studies in China.
DR30318 is composed of an anti-Claudin 18.2 single-domain antibody, an anti-HSA single-domain antibody and an anti-CD3ε scFv. DR30318 is optimized for the Immune synapse formation between T cells and tumor cells through this structure, and improve the killing efficiency. An long-acting unit is introduced to extend PK and improved the efficacy in vivo.
Based on the Multiplebody ® platform, DR10624 is designed as a tri- activity human Fc fusion protein，characterized by FGF21 activity and GLP-1 / GCG dual activity. DR10624 is expected for the treatment of metabolic diseases such as metabolic dysfunction-associated steatohepatitis (MASH) , severe hypertriglyceridemia (SHTG) ，obesity, and diabetes. DR10624 has received approval from the New Zealand Medicines and Medical Device Safety Authority (Medsafe) and the New Zealand Health and Disability Ethics Committees (HDEC) in April 2022 to conduct a Phase I clinical trial in the region. DR10624 clinical trial in China was approved by the NMPA in July 2023 and is underway in a Phase II clinical trial in China.
DR10628 is a fatty acid-modified antidiabetic polypeptide with GLP-1R/GIPR agonistic activity. In preclinical animal experiments, DR10628 showed extremely significant weight-loss and hypoglycemic effects. Indications include obesity，diabetes and metabolic dysfunction-associated steatohepatitis (MASH) .DR10628 clinical trial in China was approved by the NMPA in April 2023, and a Phase I clinical study is underway in China.
The synthesized GLP-1R / GIPR / GCG triple–hormone-receptor agonist is coupled with fatty acid chain. The proportion of GLP-1R,GIPR and GCGR activity is the best after a lot of screening. In preclinical animal experiments, DR10627 showed extremely significant hypoglycemic and weight-loss effects. Indications include obesity ,diabetes and other metabolic diseases.DR10627 clinical trial in China was approved by the NMPA in January 2022 and is underway in Phase I clinical studies in China.